Thrivent Financial for Lutherans lifted its holdings in shares of Cencora, Inc. (NYSE:COR - Free Report) by 28.5% in the 3rd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 110,499 shares of the company's stock after buying an additional 24,492 shares during the quarter. Thrivent Financial for Lutherans owned approximately 0.06% of Cencora worth $24,871,000 as of its most recent SEC filing.
Several other institutional investors also recently bought and sold shares of the company. Kingswood Wealth Advisors LLC acquired a new stake in shares of Cencora during the 2nd quarter worth approximately $655,000. Lake Street Advisors Group LLC acquired a new position in Cencora during the 1st quarter worth $836,000. Czech National Bank increased its stake in shares of Cencora by 8.3% during the second quarter. Czech National Bank now owns 31,546 shares of the company's stock worth $7,107,000 after buying an additional 2,414 shares during the period. Natixis acquired a new position in Cencora during the 1st quarter worth approximately $5,842,000. Finally, Gabelli Funds LLC purchased a new stake in shares of Cencora during the 1st quarter worth $14,093,000. 97.52% of the stock is currently owned by institutional investors and hedge funds.
Analysts Set New Price Targets
Several brokerages recently commented on COR. StockNews.com lowered shares of Cencora from a "strong-buy" rating to a "buy" rating in a research note on Friday, September 20th. Bank of America reissued a "neutral" rating and set a $245.00 price target (down previously from $275.00) on shares of Cencora in a report on Wednesday, September 18th. Evercore ISI increased their price objective on Cencora from $250.00 to $285.00 and gave the stock an "outperform" rating in a research report on Thursday, November 7th. UBS Group boosted their target price on Cencora from $275.00 to $285.00 and gave the company a "buy" rating in a report on Thursday, November 7th. Finally, Robert W. Baird increased their price target on shares of Cencora from $287.00 to $292.00 and gave the stock an "outperform" rating in a report on Thursday, November 7th. Three equities research analysts have rated the stock with a hold rating and nine have issued a buy rating to the company. Based on data from MarketBeat.com, the company currently has an average rating of "Moderate Buy" and an average price target of $271.20.
View Our Latest Report on Cencora
Insider Buying and Selling
In related news, Chairman Steven H. Collis sold 21,509 shares of the firm's stock in a transaction dated Tuesday, October 22nd. The stock was sold at an average price of $235.80, for a total transaction of $5,071,822.20. Following the sale, the chairman now directly owns 285,088 shares in the company, valued at approximately $67,223,750.40. This trade represents a 7.02 % decrease in their position. The sale was disclosed in a filing with the SEC, which can be accessed through this link. Corporate insiders own 15.80% of the company's stock.
Cencora Price Performance
COR stock traded up $2.19 on Wednesday, reaching $243.17. The company had a trading volume of 533,316 shares, compared to its average volume of 1,402,791. The company has a debt-to-equity ratio of 4.84, a quick ratio of 0.53 and a current ratio of 0.88. The company's fifty day moving average is $232.82 and its 200 day moving average is $231.29. The company has a market cap of $47.92 billion, a P/E ratio of 32.27, a PEG ratio of 1.60 and a beta of 0.44. Cencora, Inc. has a 1 year low of $195.83 and a 1 year high of $251.56.
Cencora Increases Dividend
The company also recently announced a quarterly dividend, which will be paid on Friday, November 29th. Investors of record on Friday, November 15th will be given a dividend of $0.55 per share. The ex-dividend date is Friday, November 15th. This represents a $2.20 dividend on an annualized basis and a yield of 0.90%. This is a positive change from Cencora's previous quarterly dividend of $0.51. Cencora's dividend payout ratio (DPR) is 29.29%.
About Cencora
(
Free Report)
Cencora, Inc sources and distributes pharmaceutical products. The company's U.S. Healthcare Solutions segment distributes pharmaceuticals, over-the-counter healthcare products, home healthcare supplies and equipment, and related services to acute care hospitals and health systems, independent and chain retail pharmacies, mail order pharmacies, medical clinics, long-term care and alternate site pharmacies, and other customers; provides pharmacy management, staffing, and other consulting services; supply management software to retail and institutional healthcare providers; packaging solutions to various institutional and retail healthcare providers; clinical trial support, product post-approval, and commercialization support services; data analytics, outcomes research, and additional services for biotechnology and pharmaceutical manufacturers; pharmaceuticals, vaccines, parasiticides, diagnostics, micro feed ingredients, and other products to the companion animal and production animal markets; and sales force services to manufacturers.
Featured Stories
Before you consider Cencora, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Cencora wasn't on the list.
While Cencora currently has a "Moderate Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Just getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
